Dr Grinshpun on Ultra-Sensitive ctDNA Detection in HR+ Early Breast Cancer

Описание к видео Dr Grinshpun on Ultra-Sensitive ctDNA Detection in HR+ Early Breast Cancer

Albert Grinshpun, MD, MSc, discusses the utility of ctDNA as a predictive biomarker of endocrine therapy sensitivity in patients with HR+ breast cancer.


Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center, discusses a study evaluating the potential utility of circulating tumor DNA (ctDNA) as a predictive biomarker of endocrine therapy sensitivity in patients with hormone receptor (HR)–positive early breast cancer.


See our site for more from SABCS: https://www.onclive.com/conference/sabcs

Website: https://www.onclive.com
Twitter:   / onclive  
Facebook:   / onclive  
LinkedIn:   / onclive  

Комментарии

Информация по комментариям в разработке

Похожие видео